184 related articles for article (PubMed ID: 12380948)
1. Prostate-specific antigen as a marker of disease activity in prostate cancer.
Partin AW; Hanks GE; Klein EA; Moul JW; Nelson WG; Scher HI
Oncology (Williston Park); 2002 Sep; 16(9):1218-24; discussion 1224, 1227-8 passim. PubMed ID: 12380948
[TBL] [Abstract][Full Text] [Related]
2. Prostate-specific antigen as a marker of disease activity in prostate cancer.
Partin AW; Hanks GE; Klein EA; Moul JW; Nelson WG; Scher HI
Oncology (Williston Park); 2002 Aug; 16(8):1024-38, 1042; discussion 1042, 1047-8, 1051. PubMed ID: 12201643
[TBL] [Abstract][Full Text] [Related]
3. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
[TBL] [Abstract][Full Text] [Related]
4. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
[TBL] [Abstract][Full Text] [Related]
5. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ
J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502
[TBL] [Abstract][Full Text] [Related]
6. The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy.
Ward JF; Blute ML; Slezak J; Bergstralh EJ; Zincke H
J Urol; 2003 Nov; 170(5):1872-6. PubMed ID: 14532796
[TBL] [Abstract][Full Text] [Related]
7. PSA relapse prostate cancer: the importance of tailored therapy.
Aranha O; Vaishampayan U
Urol Oncol; 2004; 22(1):62-9. PubMed ID: 14969807
[TBL] [Abstract][Full Text] [Related]
8. Treatment of men with rising prostate-specific antigen levels following radical prostatectomy.
Tzou K; Tan WW; Buskirk S
Expert Rev Anticancer Ther; 2011 Jan; 11(1):125-36. PubMed ID: 21166517
[TBL] [Abstract][Full Text] [Related]
9. Radiotherapy for locally recurrent prostate cancer.
Kirkpatrick JP; Anscher MS
Clin Adv Hematol Oncol; 2005 Dec; 3(12):933-42. PubMed ID: 16555435
[TBL] [Abstract][Full Text] [Related]
10. Conformal radiotherapy for detectable PSA following radical prostatectomy: efficacy and predictive factors of recurrence.
Delongchamps NB; Zerbib M; Mejean A; Rouach Y; Debre B; Peyromaure M
Can J Urol; 2009 Oct; 16(5):4813-9. PubMed ID: 19796456
[TBL] [Abstract][Full Text] [Related]
11. [Rising Prostate Specific Antigen following treatment with curative intention].
Jakobsen H; Pedersen KV
Ugeskr Laeger; 2007 May; 169(20):1907-9. PubMed ID: 17553369
[TBL] [Abstract][Full Text] [Related]
12. [PSA and follow-up after treatment of prostate cancer].
Benchikh El Fegoun A; Villers A; Moreau JL; Richaud P; Rebillard X; Beuzeboc P
Prog Urol; 2008 Mar; 18(3):137-44. PubMed ID: 18472065
[TBL] [Abstract][Full Text] [Related]
13. The utility of PSA doubling time to monitor prostate cancer recurrence.
Wieder JA; Belldegrun AS
Mayo Clin Proc; 2001 Jun; 76(6):571-2. PubMed ID: 11393493
[No Abstract] [Full Text] [Related]
14. Early detection of recurrent prostate cancer with an ultrasensitive chemiluminescent prostate-specific antigen assay.
Ellis WJ; Vessella RL; Noteboom JL; Lange PH; Wolfert RL; Rittenhouse HG
Urology; 1997 Oct; 50(4):573-9. PubMed ID: 9338734
[TBL] [Abstract][Full Text] [Related]
15. Prostate-specific antigen in prostate cancer: a case study in the development of a tumor marker to monitor recurrence and assess response.
Small EJ; Roach M
Semin Oncol; 2002 Jun; 29(3):264-73. PubMed ID: 12063679
[TBL] [Abstract][Full Text] [Related]
16. Stratification of patient risk based on prostate-specific antigen doubling time after radical retropubic prostatectomy.
Tollefson MK; Slezak JM; Leibovich BC; Zincke H; Blute ML
Mayo Clin Proc; 2007 Apr; 82(4):422-7. PubMed ID: 17418069
[TBL] [Abstract][Full Text] [Related]
17. Usefulness of the nadir value of serum prostate-specific antigen measured by an ultrasensitive assay as a predictor of biochemical recurrence after radical prostatectomy for clinically localized prostate cancer.
Sakai I; Harada K; Kurahashi T; Muramaki M; Yamanaka K; Hara I; Inoue TA; Miyake H
Urol Int; 2006; 76(3):227-31. PubMed ID: 16601384
[TBL] [Abstract][Full Text] [Related]
18. [The value of PSA follow-up in recurrent prostate carcinoma after radical prostatovesiculectomy].
Trinkler F; Hauri D
Helv Chir Acta; 1994 Dec; 60(6):1081-5. PubMed ID: 7533147
[TBL] [Abstract][Full Text] [Related]
19. Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database.
Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC;
J Urol; 2003 Jun; 169(6):2136-41. PubMed ID: 12771735
[TBL] [Abstract][Full Text] [Related]
20. Prostate-specific antigen kinetics in localized and advanced prostate cancer.
Fitzpatrick JM; Banu E; Oudard S
BJU Int; 2009 Mar; 103(5):578-87. PubMed ID: 19210674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
